title: Reduction of burn scar formation by halofuginone-eluting silicone gel sheets: a controlled study on nude mice.
abstract: Burn scar formations can cause disfiguration and loss of dermal function. The purpose of this study was to examine whether application of modified silicone gel sheets with an antifibrotic drug halofuginone-eluting hybrid surface produce an effect on scar development. There were a total of 2 animal groups. The athymic nude mice (nu/nu) of both groups underwent transplantation of full-thickness human skin grafts onto their backs and setting of partial thickness burn injury. The status of local scar development was observed over a period of 3 months after the application of silicone gel sheets and also after application of surface-modified halofuginone-eluting silicone gel sheets. Subsequently, via real-time polymerase chain reaction, the cDNA levels from key mediators of scar formation (transforming growth factor beta, COL1A1, connective tissue growth factor, fibroblast growth factor 2, matrix metalloproteinase 2, matrix metalloproteinase 9) were established and statistically evaluated. In comparison with uncoated silicone gel sheets, the application of halofuginone-eluting silicone gel sheets lead to a significant difference in gene expression activity in scar tissue. Halofuginone-eluting hybrid surface silicone gel sheets significantly increase the antiscarring effect of adhesive silicone gel sheets by deceleration and downregulation of scar development by normalization of the expression activity.
authors.affiliation: Department of Trauma, Hand, Plastic and Reconstructive Surgery, Würzburg University Hospital, Oberdu¨rrbacher Str. 6, Würzburg, Germany. zeplin_p@chirurgie.uni-wuerzburg.de
authors.forename: Philip H
authors.initials: PH
authors.lastname: Zeplin
mesh_terms: D000818:Animals; D002056:Burns / Q000150:complications* / Q000601:surgery*; D017439:Cicatrix, Hypertrophic / Q000209:etiology / Q000517:prevention & control*; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D010880:Piperidines / Q000627:therapeutic use*; D011500:Protein Synthesis Inhibitors / Q000627:therapeutic use; D052999:Quinazolinones / Q000627:therapeutic use*; D020034:Silicone Gels; D016038:Skin Transplantation / Q000009:adverse effects / Q000379:methods*
chemical_list: D020099:Coated Materials, Biocompatible; D010880:Piperidines; D011500:Protein Synthesis Inhibitors; D052999:Quinazolinones; D020034:Silicone Gels; C010176:halofuginone